Archives of Dermatological Research最新文献

{"title":"A cross-sectional analysis of the readability of online information for Mohs surgery in English and Spanish.","authors":"Jordan K Bui, Peter Halloran, Ochanya Ogah, Isabella Camacho-Hubbard, Keyvan Nouri, Ashley Wysong","doi":"10.1007/s00403-025-04289-6","DOIUrl":"https://doi.org/10.1007/s00403-025-04289-6","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":"788"},"PeriodicalIF":1.8,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of inflammatory skin disorders in patients with inflammatory bowel disease (IBD).","authors":"Shahin Hamzelou, Nasser Ebrahimi Daryani, Elham Yousefi, Seyed Farshad Allameh, Maryam Nasimi, Sina Naderi, Sepehr Boroumand Sani, Navid Namakizadeh Esfahani","doi":"10.1007/s00403-025-04282-z","DOIUrl":"https://doi.org/10.1007/s00403-025-04282-z","url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) is a chronic inflammatory disorder, which primarily affects the gut, but is not restricted to the intestinal tract. IBD is result of a complex interplay between a dysfunctional host immune response and environmental triggers. Extraintestinal manifestations (EIMs) are frequently observed in patients with IBD. The aim of this study was to evaluate the prevalence and features of the major cutaneous manifestations and associating factors in patients with IBD. This cross-sectional study was conducted on patients with IBD who were referred to gastroenterology and dermatology outpatient clinics in Imam Khomeini Hospital Complex, in Tehran, Iran, between March 2020 and March 2021. All patients underwent a body examination by a gastroenterologist and dermatologist. We used SPSS (version 25) to run appropriate statistical tests to analyze any relationship between skin diseases, and socio-demographic and disease-related characteristics of the patients, as well as medications used. A total of 226 patients were included in this study of which 59 (26.1%) were diagnosed with CD and 167 (73.9%) with UC. Eighty-six participants (38.1%) of all IBD patients (52.5% of CD patients and 32.9% of UC patients) had skin disease at the time of examination. Patients with CD were significantly more likely to have skin disease at the time of examination or while IBD was active (p = 0.008 and p = 0.019, respectively). Aphthous stomatitis and atopic dermatitis were the most frequent skin disease observed in all IBD patients (11.1% for both) as well as UC patients, whereas perianal fissure was the most frequent cutaneous manifestation in CD patients. Psoriasis and aphthous stomatitis were more common in female patients (p = 0.046 and p = 0.004, respectively). Skin diseases were generally more frequent in female (p = 0.001) and married patients (p = 0.015). Our research revealed that aphthous stomatitis and atopic dermatitis were the most common skin-related extraintestinal manifestations (EIMs) observed in all patients with inflammatory bowel disease (IBD). Furthermore, individuals with Crohn's disease (CD) were more prone to developing skin manifestations. Women and married individuals are considered high-risk groups for skin lesions, and it is advisable for these patients to undergo regular skin examinations.</p>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":"786"},"PeriodicalIF":1.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Omalizumab in the treatment of CSU: a meta-analysis of a randomized controlled trial.","authors":"Wentao Zhang, Xue Cao, Lixia Liu","doi":"10.1007/s00403-025-04283-y","DOIUrl":"10.1007/s00403-025-04283-y","url":null,"abstract":"<p><p>To systematically evaluate the efficacy and safety of omalizumab in the treatment of chronic spontaneous urticaria (CSU) through a meta-analysis. PubMed, Cochrane Library, and Embase databases were searched for randomized controlled trials (RCTs) comparing omalizumab with placebo in CSU. Two researchers independently screened studies, extracted data, and assessed quality. Efficacy outcomes, including the 7-day Urticaria Activity Score (UAS7), Itch Severity Score (ISS), hive count, and Dermatology Life Quality Index (DLQI), as well as safety outcomes (adverse event rates), were analyzed using RevMan 5.3 software across different doses (75, 150, 300, and 600 mg). Twelve RCTs involving 2,738 participants (2,090 in omalizumab groups, 648 in placebo) were included①Efficacy: The proportion of patients achieving UAS7 < 6 was significantly higher in the omalizumab group (OR = 3.29, 95% CI:1.16-9.38, P = 0.03), with the 300 mg dose showing optimal efficacy (OR = 7.60, 95% CI:5.44-10.62, P < 0.001).The 300 mg dose significantly reduced UAS7 (MD = 12.20, 95% CI:9.65-14.76), ISS (MD = 5.26, 95% CI:4.42-5.36), and hive count (MD = 6.83, 95% CI:5.73-7.94) compared to placebo (all P < 0.001).DLQI improvement was also greater with 300 mg (MD = 3.26, 95% CI:1.78-4.73, P < 0.0001).②Safety: Adverse events were more frequent in the omalizumab group (OR = 1.24, 95% CI:1.04-1.49, P = 0.02), though most were mild. Omalizumab effectively alleviates CSU symptoms and improves quality of life, with the 300 mg/month dose demonstrating optimal efficacy. Clinicians should prioritize this dose while monitoring short-term adverse effects. Further studies are needed to confirm long-term safety.</p>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":"785"},"PeriodicalIF":1.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term efficacy and safety of fractional 1064-nm picosecond laser for minimization of post-mammoplasty scar in Asians: a prospective randomized controlled study.","authors":"Panwadee Thongjaroensirikul, Rona Maria R Abad-Constantino, Supisara Wongdama, Visnu Lohsiriwat, Woraphong Manuskiatti","doi":"10.1007/s00403-025-04280-1","DOIUrl":"10.1007/s00403-025-04280-1","url":null,"abstract":"<p><p>Various types of lasers and energy-based devices have been used to prevent scar formation following primary surgical wound closure. While picosecond lasers have demonstrated potential in treating hypertrophic scars, limited data exists regarding their role in minimizing surgical scar formation. This study aimed to evaluate the safety and effectiveness of a fractional 1064-nm picosecond laser in reducing scar formation after mammoplasty in Asian patients. Eighteen patients with bilateral mammoplasty scars were enrolled, and treatment commenced within one month after surgery. For each patient, one side was randomly selected to receive four laser treatment sessions at four-week intervals, while the contralateral side served as an untreated control. Scar width and thickness were measured using a calibrated caliper, and additional evaluations were performed using the Antera^® 3D imaging system and the Patient and Observer Scar Assessment Scale (POSAS). Seventeen patients completed the study. Significant reductions in scar width and thickness were observed on the treated side, with average reductions of 75.3% and 84.9%, respectively, six months post-treatment. In contrast, no significant changes were found in the untreated scars. Imaging and subjective assessments further supported the efficacy of the laser treatment. The procedure was well-tolerated, with only mild and transient postinflammatory hyperpigmentation (PIH) reported in 11% of patients. These findings support the fractional 1064-nm picosecond laser as a safe and effective prophylactic option for minimizing postsurgical scarring in Asian patients.</p>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":"784"},"PeriodicalIF":1.8,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144155915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trichoblastic carcinoma: a systematic review of an aggressive follicular neoplasm with an emphasis on Mohs micrographic surgery in management","authors":"Leo Wan,&nbsp;Lanah Almatroud,&nbsp;Aileen Park,&nbsp;Amor Khachemoune","doi":"10.1007/s00403-025-04275-y","DOIUrl":"10.1007/s00403-025-04275-y","url":null,"abstract":"<div><p>Trichoblastic carcinoma (TC) is a rare and aggressive adnexal tumor with a high potential for metastasis and frequent misdiagnosis due to its histopathologic similarity to basal cell carcinoma (BCC). This systematic review consolidates current knowledge on TC, including its clinical presentation, histopathology, treatment approaches, and outcomes. TC most commonly presents on the face and scalp as a nodular lesion, often with ulceration. Histologically, it is characterized by basaloid islands, nuclear palisading, and high mitotic activity. Differentiating TC from BCC is crucial, as TC exhibits a significantly higher metastatic potential. Surgical excision remains the primary treatment, with Mohs micrographic surgery offering better recurrence-free outcomes. Emerging therapies, including targeted treatments and immunotherapy, have shown potential in select cases. However, due to the lack of standardized management guidelines, further research is needed to refine diagnostic criteria, optimize treatment strategies, and improve patient outcomes.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Granular cell tumor of the foot mimicking squamous cell carcinoma identified during Mohs micrographic surgery: a case report and review of the literature","authors":"Umer Nadir,&nbsp;Lara M. Jabbour,&nbsp;Brett C. Neill,&nbsp;Cary Chisholm,&nbsp;Stanislav N. Tolkachjov","doi":"10.1007/s00403-025-04279-8","DOIUrl":"10.1007/s00403-025-04279-8","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144125532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased gut short-chain fatty acids in cutaneous T-cell lymphoma: a novel insight","authors":"Zachary O. Thomas,&nbsp;JoJo Holm,&nbsp;Morgan McCarthy,&nbsp;William Nguyen,&nbsp;Yanzhen Pang,&nbsp;Lauren P. Chrisman,&nbsp;Joan Guitart,&nbsp;Michael B. Burns,&nbsp;Xiaolong Alan Zhou","doi":"10.1007/s00403-025-04285-w","DOIUrl":"10.1007/s00403-025-04285-w","url":null,"abstract":"<div><p>Short-chain fatty acids (SCFAs) are critical metabolites produced by gut microbiota that play a key role in modulating inflammation and regulating systemic immunity, including against cancer. Decreases in SCFAs can foster a permissive tumor immune environment. Recent studies have shown that cutaneous T-cell lymphoma (CTCL) patients exhibit increasing gut dysbiosis and loss of bacteria predicted to produce SCFAs with increasing disease severity. To investigate this functional connection, we collected stool swab samples from 15 individuals– 8 mycosis fungoides (MF) patients and 7 matched healthy controls (HC)– and quantified concentrations of four SCFAs (acetate, propionate, isovalerate, butyrate) via liquid chromatography-mass spectrometry. Our results demonstrated significantly reduced acetate and propionate concentrations in MF patients when compared to HC (both <i>p</i> = 0.027). Total measured SCFA concentrations were on average lower in MF versus HC, but did not achieve statistical significance (<i>p</i> = 0.063). Both propionate and acetate have been previously demonstrated to promote tumor apoptosis, inhibit tumor proliferation, and enhance antitumor immunity. Thus, dysbiosis-associated reductions in SCFAs may be another contributive factor in the immune dysfunction observed in CTCL. Our pilot findings add to the growing body of knowledge implicating the gut microbiota-SCFA axis in CTCL pathogenesis and offer potential new avenues for therapeutic intervention.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144125630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision in terminology: classifying genetic influence in hidradenitis suppurativa","authors":"Dillon Mintoff,&nbsp;Nikolai P. Pace","doi":"10.1007/s00403-025-04284-x","DOIUrl":"10.1007/s00403-025-04284-x","url":null,"abstract":"","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144125501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sexual dysfunction in women with facial melasma: a case control study","authors":"Serap Koran Karadogan,&nbsp;Bora Irer","doi":"10.1007/s00403-025-04273-0","DOIUrl":"10.1007/s00403-025-04273-0","url":null,"abstract":"<div><h3>Background</h3><p>Melasma is a well-established reason of psychosocial problems as well as other dermatoses. Unlike common psychological morbidities, such as depression and anxiety, sexual dysfunction (SD) has been scarcely explored. We aimed to assess the occurrence of SD in melasma using a prospective case-control study.</p><h3>Methods</h3><p>Sexual function of melasma patients (Group I) and healthy controls (Group II) were compared using Female Sexual Function Index (FSFI). Severity of melasma was assessed using Modified Melasma and Area and Severity Index (mMASI). Age in both groups and severity in Group I were divided into subgroups. Possible effects of these variables on FSFI scores were analysed.</p><h3>Results</h3><p>109 (55 in Group I; 54 in Group II) patients were included. Median FSFI scores of Group I were significantly lower than Group II (27,3 vs. 29,4). Arousal, orgasm and satisfaction were significantly lower in Group I. Median total FSFI scores and percentage of SD were not influenced by age and severity of melasma. Patients with mild melasma had better lubrication results than patients with moderate and severe melasma. Pain/discomfort domain score was higher in patients with severe melasma.</p><h3>Conclusions</h3><p>Dermatologists should keep in mind that melasma, particularly on face, as well as other dermatoses, may also impair the females’ self-esteem and relationships, thereby affect sexual well-being and these patients should be evaluated in a multidisciplinary approach, if necessary. We think our study highlights the need for a more detailed approach to the further studies of SD in females with melasma.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144125631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study—IL AD (Italian Landscape Atopic Dermatitis)","authors":"Luca Potestio,&nbsp;Cataldo Patruno,&nbsp;Alessandra Narcisi,&nbsp;Antonio Costanzo,&nbsp;Luciano Ibba,&nbsp;Luigi Gargiulo,&nbsp;Piergiorgio Malagoli,&nbsp;Michela Ortoncelli,&nbsp;Simone Ribero,&nbsp;Luca Mastorino,&nbsp;Francesco Leo,&nbsp;Silvia Mariel Ferrucci,&nbsp;Luisa Angileri,&nbsp;Francesca Barei,&nbsp;Luca Stingeni,&nbsp;Katharina Hansel,&nbsp;Claudio Sciarrone,&nbsp;Giampiero Girolomoni,&nbsp;Martina Maurelli,&nbsp;Caterina Foti,&nbsp;Benedetta Tirone,&nbsp;Anna Balato,&nbsp;Maria Esposito,&nbsp;Giovanni Paolino,&nbsp;Santo Raffaele Mercuri,&nbsp;Elena Pezzolo,&nbsp;Paola Savoia,&nbsp;Claudio Brescia,&nbsp;Maddalena Napolitano","doi":"10.1007/s00403-025-04278-9","DOIUrl":"10.1007/s00403-025-04278-9","url":null,"abstract":"<div><p>Atopic dermatitis (AD) prevalence in elderly patients is increasing. Clinically, elderly AD may present with atypical phenotypes, making the diagnosis difficult. Moreover, treatment challenges arise due to treatment-resistance, comorbidities, polypharmacy, and contraindications to existing therapies. Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) may offer a valuable alternative. However, their use in elderly populations remains unclear, as older patients are often excluded from clinical trials, and several concerns have been raised about their safety in this category of subjects. This study aimed to evaluate the efficacy and safety of JAK inhibitors in elderly patients with moderate-to-severe AD. A 52-week, multicenter, real-life study was performed enrolling patients aged ≥ 60 years affected by moderate-to-severe AD undergoing treatment with JAK inhibitors for at least 16 weeks across 16 dermatological centers in Italy. Disease severity was assessed at baseline, week (W) 4, 16, 24, and 52 using the Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), and Pruritus-Numerical Rating Scale (P-NRS). Adverse events (AEs) were recorded at each follow-up. A total of 72 patients met the inclusion criteria [abrocitinib: 13 (18.06%); baricitinib: 6 (8.33%); upadacitinib: 53 (73.61%)]. Of these, 72 (100.0%) achieved W16 follow-up with 33 (45.83%) and 26 (36.11%) subjects reaching W24 and W52, respectively. At baseline, mean EASI, DLQI and P-NRS were 21.22 ± 10.38, 18.21 ± 7.33, and 7.84 ± 1.94, respectively. A significant improvement in all scores was observed starting from W4 [EASI: 4.77 ± 5.07, DLQI: 4.01 ± 3.98, P-NRS: 1.66 ± 1.83 (p &lt; 0.0001 for all)], continuing to improve up to W52 [EASI: 0.81 ± 1.27, DLQI: 0.31 ± 0.63, P-NRS: 0.42 ± 1.03; (p &lt; 0.0001 for all)]. No treatment interruptions or modifications for ineffectiveness or AEs were registered. No statistically significant differences in terms of efficacy and safety were found among the treatment groups. JAK inhibitors demonstrated significant efficacy and an acceptable safety profile in elderly AD patients.</p></div>","PeriodicalId":8203,"journal":{"name":"Archives of Dermatological Research","volume":"317 1","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00403-025-04278-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144117811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}